Salt: Omeprazole
Therapeutic Description: Antipeptic Ulcerants
Category: Proton pump inhibitor.
Pregnancy: Risk cannot be ruled out.
Lactation: Contraindicated or not recommended.
Precautions: Exclude malignancy before treatment. Hepatic impairment. Monitor serum B12 in severely ill children on long term treatment.
Oesophageal reflux disease, reflux oesophagitis. Long-term management of acid-reflux disease. Duodenal and benign gastric ulcers including those complicating NSAID therapy. Duodenal ulcers associated with H. pylori. Zollinger-Ellison syndrome. Prophylaxis of acid aspiration during general anaesthesia.
ORAL: Reflux oesophagitis: Adults: 20 mg od x 4 weeks, extend for a further 4-8 weeks if not fully healed. Refractory cases, 40 mg od.
Acid-reflux disease: Adults: Long-term management, 10 mg od, increasing to 20 mg od if symptoms return.
Duodenal ulcer: Adults: 20 mg od x 4 weeks. Severe cases, increasing to 40 mg od. Prevention of relapse, 10 mg od, increasing to 20 mg od if symptoms return.
DU with H. pylori: Adults: 40 mg od with amoxicillin 1.5-2 gm od x 2 weeks.
Gastric ulcer: Adults: 20 mg od x 8 weeks. Severe cases, increase to 40 mg od.
Zollinger-Ellison syndrome: Adults: 60 mg od adjusted to response. Usual maintenance, 20-120 mg daily. Doses over 80 mg daily, give in bid doses.
Intermittent or continuous IV infusion in Glucose 5% or NaCl 0.9%. Reconstitute each 40 mg vial with infusion fluid and dilute to 100 mL; for intermittent infusion, give 40 mg over 20-30 min. Stable for 3 hours in glucose 5% or 12 hours in NaCl 0.9%.
Diazepam, phenytoin, warfarin, digoxin, ketoconazole, itraconazole.
Headache, GI upset, skin rashes, paraesthesia, dizziness, somnolence, insomnia, arthralgia, myalgia. Increased risk of GI infections. Increase in liver enzymes, thrombocytopenia.
Strength Pack Size PKR
20 mg14's144.00

Your medicine formula resulted in the following types of medicine type. Please select to proceed.